UroGen Pharma Ltd
URGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.88B
Close$
$-31.37
180% downside
Current Fair Value
180% downsideOvervalued by 180% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.88 Billion |
|---|---|
| Enterprise Value | $1.97 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.19 |
| Beta | 1.58 |
| Outstanding Shares | 50,182,758 |
Return
| Return on Equity | 107.22% |
|---|---|
| Return on Assets | -52.51% |
| Return on Invested Capital | -55.46% |
Valuation & Multiples
| P/E Ratio | -14.02 |
|---|---|
| PEG | 30.33 |
| Price to Sales | 19.6 |
| Price to Book Ratio | -13.06 |
| Enterprise Value to Revenue | 14.04 |
| Enterprise Value to EBIT | -17.52 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -1.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$44.83 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$62.16 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7613▲ 60.73% |
|---|---|
| Total Calls | 226,200▼ 83.42% |
| Total Puts | 172,200▼ 18.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.29%▲ 3.34% |
|---|---|
| Total Invested | $834.80M▼ 18.44% |
| Investors Holding | 178▲ 2.00% |
ESG Score
No data
About UroGen Pharma Ltd
CEO: Elizabeth Barrett